Search company, investor...


Founded Year



Other Investors | Alive

About Corimmun

focused on the development of therapeutics for the treatment of congestive heart failure and atherosclerosis.

Headquarters Location

Am Klopferspitz 19



Missing: Corimmun's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Corimmun's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Corimmun Patents

Corimmun has filed 1 patent.

patents chart

Application Date

Grant Date


Related Topics




Immune system, Immunology, Clusters of differentiation, Glycoproteins, Monoclonal antibodies


Application Date


Grant Date



Related Topics

Immune system, Immunology, Clusters of differentiation, Glycoproteins, Monoclonal antibodies



Corimmun Frequently Asked Questions (FAQ)

  • When was Corimmun founded?

    Corimmun was founded in 2006.

  • What is Corimmun's latest funding round?

    Corimmun's latest funding round is Other Investors.

  • Who are the investors of Corimmun?

    Investors of Corimmun include High-Tech Grunderfonds, Bayern Kapital and BioM Venture Capital & Fonds.

  • Who are Corimmun's competitors?

    Competitors of Corimmun include Juventas Therapeutics, Nora Therapeutics, Cerenis Therapeutics, Fibrotech Therapeutics, Aldagen and 10 more.

Compare Corimmun to Competitors

Phrixus Pharmaceuticals

Phrixus Pharmaceuticals is developing Carmeseal (poloxamer 188 or P188) for Duchenne muscular dystrophy and acute decompensated heart failure. Carmeseal has been shown to improve the efficiency of damaged hearts to pump blood and to improve the performance of damaged diaphragms. When Carmeseal, which acts as a molecular band-aid, is infused into the bloodstream, it encounters and binds to microscopic tears in the muscle. This prevents the pathological leak of calcium into the cells, which causes calcium overload and keeps the muscle from performing as required. Carmeseal, which has been shown to be effective in four animal models of DMD and heart failure, is expected to have its effect in patients with DMD irrespective of the genetic defect that causes the disease.

Zinc Therapeutics

Zinc Therapeutics Canada Inc is focusing on development of new zinc-containing therapeutic compounds for heart, stroke and other disorders.

NellOne Therapeutics Logo
NellOne Therapeutics

NellOne Therapeutics is a regenerative-medicine spinout of the U.S. Department of Energy's Oak Ridge National Laboratory (ORNL). The start-up, in the proof-of-efficacy stage, is dedicated to exploring the creation of protein therapeutics for their potential in restoring tissue mass andfunction in patients recovering from heart attacks. Current therapeutic approaches, such as those based on stem cells, have shown the potential to restore tissue mass, but with only limited recovery of function. General Partner Tracy Warren is acting CEO and a member of the Board of Directors. (See deal announcement.)

Kardia Therapeutics

Kardia Therapeutics, Inc. is a research-stage biotechnology company focused on the development of cardiac regenerative therapies in the areas myocardial infarction and heart failure. Kardia Therapeutics' portfolio of technologies aims to utilize three related approaches: 1) Adult Cardiac Progenitor Cells, 2) Stem Cell Optimization Technologies, and 3) Homing/Growth Factor Therapies. Because the heart has a limited capacity for self-regeneration, Kardia's technologies have the potential to offer improved patient outcomes compared to existing treatments.


ThyroChek is the only available rapid test for elevated TSH approved by the FDA. It is a rapid, qualitative test for elevated TSH, thyroid stimulating hormone, a clinical indicator of hypothyroidism. Screening Devices Canada is producing products for the thyroid health market in the United States which is a market valued at $1.2B annually.

Intarcia Therapeutics

Intarcia Therapeutics is a biopharmaceutical company based in Boston, Massachusetts. Intarcia is engaged in the development of a pipeline of products for the proprietary Medici Drug Delivery System comprised of three technologies: A stabilization technology that allows for proteins, peptides, antibody fragments, and other highly potent small molecules to be stabilized at or above human body temperatures, a matchstick-sized osmotic mini-pump that is placed under the dermal layer of skin to deliver a continuous and consistent flow of medication, and a placement technology including proprietary tools designed to provide an optimal user experience.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.